RICHEZ, Christophe; TRUCHETET, Marie Elise

doi:10.1080/14656566.2021.1967929

Métadonnées

Licence d’utilisation du document

RICHEZ, Christophe
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]

TRUCHETET, Marie Elise
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]

Langue

Article de revue

Ce document a été publié dans

Expert Opinion on Pharmacotherapy. 2021-08-26, vol. 22, n° 18, p. 2435–2444

Résumé en anglais

Introduction: Despite the availability of an extensive armamentarium, rheumatoid arthritis (RA) remains a therapeutic challenge for rheumatologists. Janus kinase inhibitors (JAKi) are an emerging class of targeted therapies. The number of JAKi has been growing and to date, filgotinib is the latest JAKi to be approved for use in RA. Areas covered: This review focuses on the pharmacodynamics, pharmacokinetics, efficacy and safety of filgotinib in patients with RA. Expert opinion: Filgotinib is an oral targeted synthetic disease-modifying antirheumatic drug (DMARD) that specifically inhibits JAKi. Filgotinib monotherapy, or a combination regimen with conventional synthetic (cs) DMARDs, has demonstrated efficacy in decreasing disease activity, with a well-managed safety profile in patients with early RA naive to DMARDs, and in RA that does not adequately respond to csDMARDs and/or biologic DMARDs. The selective inhibition of JAK1 may confer an improved safety profile, but further study is required as a potential testicular toxicity has been suggested. Filgotinib offers several advantages: oral administration, rapidity of action, efficacy as monotherapy, and demonstrated activity in difficult to treat RA. However, the placement of filgotinib in the therapeutic arsenal for RA may be influenced by the ongoing collection of long-term safety data from JAKi as a class.< Réduire

Mots clés en anglais

Filgotinib

Herpes zoster virus

JAK1

Monotherapy

Rheumatoid arthritis

Spermatogenesis

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Evaluating filgotinib for the treatment of rheumatoid arthritis

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche